

CA19-9; Clone 121 SLE

Catalog Number	Format	Volume
A00107-0002	(Ready-To-Use)	2 ml
A00107-0007	(Ready-To-Use)	7 ml
A00107-0025	(Ready-To-Use)	25 ml
A00107-C	(Concentrate)	1 ml

Intended Use

For In-Vitro Diagnostic Use. This antibody is intended for the qualitative visualization of the anatomical elements listed in the Specificity section. It is intended to be used within an Immunohistochemistry (IHC) procedure on formalin-fixed paraffin-embedded (FFPE) human tissue followed by visualization by light microscopy.

Description

Titer/Working Dilution: Ready-to-Use: No further dilution required.
Concentrate: Suggested dilution is 1:25-50

Species: Mouse
Immunogen: Precipitin lines obtained after immunodiffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as immunogen for this CA19-9 antibody.

Clone: 121SLE
Isotype: IgM, Kappa
Format: Ready-To-Use antibody has been pre-titered and quality controlled to work on formalin-fixed paraffin-embedded as well as acetone fixed cryostat tissue sections. No further titration is required.
Concentrate antibody is provided in a phosphate buffered saline containing 1% BSA.

Specificity: CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewis a structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis a and/or Lewis b blood group antigens. In normal tissues, sialyl Lewis a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.


Species Reactivity: Human.
Cellular Localization: Luminal surface and cytoplasm
Microbiological State: Nonsterile

Materials and Reagents Required but not Provided

- Control tissue and reagents
- Xylene, graded alcohols, and deionized/distilled water
- Antibody Diluent.
- IHC detection system. Suggested: ScyTek Cat# ABZ125 "CRF Anti-Polyvalent HRP Polymer" and ScyTek Cat# ACV500 "DAB Chromogen/Substrate Kit (High Contrast)".
- Wash buffer for rinses (ScyTek Cat# TBT500)
- HIER Retrieval Solution
- Hematoxylin counterstain and bluing reagent (ScyTek Cat# HMM500 and BRT500)

8. Mounting medium and coverslips

Note: ScyTek Laboratories has a wide range of IHC reagents and ancillaries that can be found at scytex.com.



Procedure

1. **Tissue Section Pretreatment (Highly Recommended):** Staining of formalin fixed paraffin embedded tissue sections is significantly enhanced by pretreatment with Tis-EDTA HIER Solution (10x) pH 9.0 (ScyTek catalog# TES500) or Citrate Plus (10x) HIER Solution (ScyTek catalog# CPL500)

2. **Primary Antibody Incubation Time:** We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.

3. **Visualization:** For maximum staining intensity we recommend the "UltraTek HRP Anti-Polyvalent Lab Pack" (ScyTek catalog# UHP125, see IFU for instructions) combined with the "DAB Chromogen/Substrate Bulk Pack (High Contrast)" (ScyTek catalog# ACV500, see IFU for instructions).

Storage and Stability

Do not Freeze. Store at 2-8°C. Return to 2-8° immediately after use. Do not use after expiration date printed on label. Verify visually that antibody has not been contaminated before use. Do not use if reagent becomes cloudy or precipitates.


Limitations

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used. This data sheet's recommendations and procedures were validated using ScyTek IHC reagents and may not be suitable for other detection systems.

Precautions

1. Contains Sodium Azide as a preservative (0.09% w/v), do not ingest. Sodium Azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal,

Storage: 2° C  8° C

 ScyTek Laboratories, Inc.
205 South 600 West
Logan, UT 84321
U.S.A.




Emergo Europe
Westervoortsedijk 60
6827 AT Arnhem, The Netherlands

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 – Tel. (435) 755-9848 - Fax (435) 755-0015 - www.ScyTek.com

flush with large volumes of water to prevent azide build-up in plumbing. This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200, OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

2. Do not pipette by mouth.
3. Avoid contact of reagents and specimens with skin and mucous membranes.
4. Avoid microbial contamination of reagents or increased nonspecific staining may occur.
5. The user must validate any procedures and recommendations that differ from this data sheet.
6. The SDS may be found at scytek.com


References

1. Nomoto S; Nakao A; Ichihara T; Takagi H. Hepato-Gastroenterology, 1995 Sep-Oct, 42(5):717-23.
2. Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J. European Journal of Cancer, 1996 Jan, 32A(1):63-8.
3. Tsuruta T; Ogawa A; Ishii K; Ikado S. Urologia Internationalis, 1997, 58(1):20-4.
4. van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J. Hepato-Gastroenterology, 1996 May-Jun, 43(9):710-3.
5. Kodera Y; Yamamura Y; Torii A; Uesaka K; Hirai T; Yasui K; Morimoto T; Kato T; Kito T. American J of Gastroenterology, 1996, 91:49-53.
6. Furuya N; Kawa S; Hasebe O; Tokoo M; Mukawa K; Maejima S; Oguchi H. British Journal of Cancer, 1996 Feb, 73(3):372-6.
7. Wang FM; Tsai LC; Chang ZN; Han SH; Tsao D. Proceedings of the National Science Council, Republic of China. Part B, Life Sciences, 1985 Apr, 9(2):119-25.

Warranty

No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

Storage: 2° C  8° C



ScyTek Laboratories, Inc.
205 South 600 West
Logan, UT 84321
U.S.A.



EC REP

Emergo Europe
Westervoortsedijk 60
6827 AT Arnhem, The Netherlands